single non drug eluting stent implantation for bifurcation lesion of coronaiy artery相关文献:
Drug-coated balloon in the treatment of coronary bifurcation lesions: A hope or hype?
Dash D, Mody R, Ahmed N, Malan SR, Mody B.
Indian Heart J. 2022 Nov-Dec;74(6):450-457. doi: 10.1016/j.ihj.2022.10.193. Epub 2022 Nov 5.
PMID:36347323
Very long-term clinical outcomes after percutaneous coronary intervention for complex vs non-complex lesions: 10-year outcomes following sirolimus-eluting stent implantation.
Riku S, Suzuki S, Yokoi T, Sakaguchi T, Yamamoto T, Jinno Y, Tanaka A, Ishii H, Inden Y, Murohara T.
Nagoya J Med Sci. 2022 May;84(2):352-365. doi: 10.18999/nagjms.84.2.352.
PMID:35967938
Treatment with a dedicated bifurcation sirolimus-eluting cobalt-chromium stent for distal left main coronary artery disease: rationale and design of the POLBOS LM study.
Asano T, Kogame N, Onuma Y, Modolo R, Chichareon P, Lefèvre T, Legutko J, Digne F, Morel MA, Serruys PW, Gil RJ.
EuroIntervention. 2020 Oct 23;16(8):654-662. doi: 10.4244/EIJ-D-19-00361.
PMID:31543500
Clinical outcomes of a dedicated bifurcation stent system.
Sivalingam J, Mazhar MW, Chaddad RA, Fouladvand F, Cortese B.
Comparison of single- versus two-stent techniques in treatment of unprotected left main coronary bifurcation disease.
Kim WJ, Kim YH, Park DW, Yun SC, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Park SJ.
Catheter Cardiovasc Interv. 2011 May 1;77(6):775-82. doi: 10.1002/ccd.22915. Epub 2011 Jan 4.
PMID:21520380
Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold versus everolimus-eluting stent for coronary bifurcation lesions.
Naganuma T, Kawamoto H, Panoulas VF, Latib A, Tanaka A, Mitomo S, Ruparelia N, Jabbour RJ, Chieffo A, Carlino M, Montorfano M, Colombo A.
Int J Cardiol. 2017 Nov 1;246:26-31. doi: 10.1016/j.ijcard.2017.03.123.
PMID:28867010
Treatment of coronary bifurcation lesions with bioresorbable vascular scaffolds.
Capranzano P, Gargiulo G, Capodanno D, Longo G, Tamburino C, Ohno Y, Attizzani GF, La Manna A, Di Salvo M, Francaviglia B, Grasso C, Sgroi C, Tamburino C.
Minerva Cardioangiol. 2014 Jun;62(3):229-34.
PMID:24831758
Early experience and favorable clinical outcomes of everolimus-eluting bioresorbable scaffolds for coronary artery disease in Korea.
Kwon O, Ahn JM, Kang DY, Kang SH, Lee PH, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Park DW, Park SJ.
Korean J Intern Med. 2018 Sep;33(5):922-932. doi: 10.3904/kjim.2016.368. Epub 2017 Nov 7.
PMID:29108400
Unprotected left main coronary artery bifurcation stenosis: impact of plaque debulking prior to single sirolimus-eluting stent implantation.
Tanaka N, Terashima M, Kinoshita Y, Kimura M, Nasu K, Ehara M, Tsuchikane E, Matsubara T, Asakura Y, Katoh O, Suzuki T.
J Invasive Cardiol. 2008 Oct;20(10):505-10.
PMID:18829993
First-in-man study of dedicated bifurcation cobalt-chromium sirolimus-eluting stent BiOSS LIM C - three-month results.
Gil RJ, Bil J, Kern A, Pawłowski T.
Kardiol Pol. 2018;76(2):464-470. doi: 10.5603/KP.a2017.0226. Epub 2017 Dec 1.